Menlo Therapeutics, Inc.
They are a lateâstage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis.
January 25, 2018
Jefferies, Piper Jaffray, Guggenheim Securities
To view the prospectus for Menlo Therapeutics, Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277